Issue
Copyright (c) 2023 Xiuli Liu, Jifeng Zhang, Wenzong Zhou, Jingwang Liu, Yingli Wang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes
Corresponding Author(s) : Yingli Wang
Cellular and Molecular Biology,
Vol. 69 No. 2: Issue 2
Abstract
This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. For this purpose, a total of 126 chronic heart failure patients complicated with diabetes admitted to our hospital from September 2020 to October 2021 were selected and divided into a control group and an observation group by random number table method, with 63 cases in each group. The control group received conventional drug treatment, and the observation group received fenofibrate treatment on the basis of the control group. After 12 months follow-up, the levels of blood lipid, sICAM-1, ET-1 were compared between the two groups at 3 months before and after treatment and 6, 12 months after treatment. Results showed that after 3 months of treatment, LDL-C, TG and TC were lower in the observation group than in the control group, showing a statistically significant difference (P<0.05). After 3 months of treatment, HDL-C was higher in the observation group than in the control group, showing a difference (P<0.05). After 3 months of treatment, sICAM-1 and ET-1 were lower in the observation group than in the control group, showing a difference (P<0.05). There was no significant difference in mortality after 6 months of treatment, re-hospitalization rate and mortality after 12 months of treatment between the two groups (P>0.05). The re-hospitalization rate of the observation group was 4.76% (3/63) after 6 months of treatment, which was lower than that of the control group in the same period, showing a significant difference (P<0.05). The conclusion was that fenofibrate can regulate blood lipids in chronic heart failure patients complicated with diabetes, inhibit sICAM-1 and ET-1, and reduce the re-hospitalization rate within 6 months after treatment. However, the effects on long-term re-hospitalization rate and mortality risk are consistent with those of conventional treatment.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
